Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Waste Data Preview
In 2024, Glenmark Pharmaceuticals conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards. The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Waste Recovered | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Hazardous Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Non-Hazardous Waste Disposed | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected waste data points. To access the complete dataset with full disclosures and structure, create a free account to purchase the full dataset.
Insights into Glenmark Pharmaceuticals's Waste Treatment Practices
In 2024, Glenmark Pharmaceuticals generated a total of 3,613 metric tonnes of waste.
Of this amount, 72.85% of Glenmark Pharmaceuticals's total waste generated was recovered through methods such as recycling, reuse, or composting, while 27.12% was disposed of through landfilling, incineration, or combustion.
Glenmark Pharmaceuticals's Waste Recovery Rate
How much of Glenmark Pharmaceuticals's waste is recycled or recovered?
In 2024, Glenmark Pharmaceuticals reported a total waste generation of 3,613 metric tonnes, of which 72.85% was recovered through recycling, reuse, or composting. This moderate level of recovery indicates that Glenmark Pharmaceuticals is taking steps toward improving its waste diversion practices, though there is still room to enhance recycling and recovery efforts.
Has Glenmark Pharmaceuticals reduced its environmental waste footprint over time?
Since 2021, Glenmark Pharmaceuticals's total waste generation increased by 28.26%, including a 19.64% increase in 2024, indicating a persistent upward trend that may reflect scaling operations, inefficiencies in resource use, or a lack of effective waste minimization practices.
Over the same period, Glenmark Pharmaceuticals's waste recovery rate increased by 3.33%, including a 11.22% rise in 2024, indicating growing emphasis on circularity and improved operational practices for diverting waste from disposal.
Overall, Glenmark Pharmaceuticals has seen a consistent rise in waste generation both over the long term and in the year 2024. However, the company has also steadily improved its waste recovery performance, suggesting that it is actively working to offset the environmental consequences of increased production through enhanced circularity efforts.
Glenmark Pharmaceuticals’s Waste Recovery vs. Disposal Over Time
- Total Waste Disposed
- Total Waste Recovered
Insights into Glenmark Pharmaceuticals’s Generation of Hazardous and Non-Hazardous Waste
In 2024, Glenmark Pharmaceuticals generated a total of 3,613 metric tonnes of waste.
Of this amount, 31.14% of Glenmark Pharmaceuticals's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment. 68.86% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.
Glenmark Pharmaceuticals’s Hazardous vs Non-Hazardous Waste Over Time
- Total Non-Hazardous Waste Generated
- Total Hazardous Waste Generated
How Glenmark Pharmaceuticals reduced the environmental impact of its waste?
Since 2021, Glenmark Pharmaceuticals's total waste generation increased by 28.26%, including a 19.64% rise in 2024, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.
Over the same period, Glenmark Pharmaceuticals reduced the hazardousness of its waste by 19.9%, with a further 26.07% decline in 2024, suggesting a sustained and meaningful shift toward safer waste profiles and lower environmental impact.
Overall, Glenmark Pharmaceuticals is generating more waste but has significantly reduced the share of hazardous materials, suggesting a partial decoupling of volume and toxicity that could reflect more responsible inputs or enhanced treatment.
How does Glenmark Pharmaceuticals treat its hazardous waste?
In 2024, Glenmark Pharmaceuticals reported that 1,125 metric tonnes of its total waste output were classified as hazardous. This represents 31.14% of its overall waste generation.
The company treated this hazardous waste using a combination of methods. Approximately 12.89% was managed through recovery methods, indicating a moderate integration of circular practices into its hazardous waste management. However, a significant share was still directed toward disposal, highlighting room for improvement in reducing the long-term impact of hazardous materials.